Rapid Diagnosis Possible at POC
|
By LabMedica International staff writers Posted on 05 Mar 2013 |

Image: The hand-held cobas h 232 is suitable for use in different clinical settings, from the General Practitioner’s office to the Emergency Room (Photo courtesy of Roche).
A versatile handheld device enables rapid diagnosis at point of care (POC).
In hospitals, Roche's (Burgess, United Kingdom) products can support laboratory services by providing accurate diagnosis of patient samples and enabling rapid diagnosis of medical conditions in the emergency ward, intensive care, and in the operating theatre.
Forth Valley Royal Hospital (United Kingdom) has reduced lengths of stay and ward admissions for patients presenting with chest pain, as well as ensuring rapid referral for patients with positive findings, through the introduction of a Chest Pain Assessment Unit (CPAU). This unit provides patient care and rapid access to diagnostic testing, including Troponin T testing, using the Roche point of care (POC) cardiac marker system, cobas h 232.
“Prior to opening the CPAU, patients at low risk of Acute Coronary Syndrome (ACS) were spending a long time in hospital unnecessarily, often overnight, while ACS was ruled out,” explained nurse consultant-acute medicine, Sharon Oswald. “To obtain real-time results that enable rapid decisions to be made, we introduced the Roche cobas h 232 system for point-of-care Troponin T testing. The cobas h 232 has had a huge impact on the service. Before we introduced it, Troponin T tests were batched and performed four times per day in the laboratory. There were sometimes delays in getting the bloods to the laboratory and then in getting results back. Now, with the cobas h 232 systems, we are able to obtain results in real time, which allows faster decision making.”
“The cobas h 232 system is very sensitive,” Sharon added. “A six month comparative evaluation demonstrated that we were getting comparable results to the laboratory method. We still send positives to the laboratory for confirmation but negative results do not require further confirmation. This means [we can exclude] ACS more quickly, allowing earlier discharge. Patients that require further investigation or care can be referred immediately or given a planned return appointment.”
Related Links:
Roche
Forth Valley Royal Hospital
In hospitals, Roche's (Burgess, United Kingdom) products can support laboratory services by providing accurate diagnosis of patient samples and enabling rapid diagnosis of medical conditions in the emergency ward, intensive care, and in the operating theatre.
Forth Valley Royal Hospital (United Kingdom) has reduced lengths of stay and ward admissions for patients presenting with chest pain, as well as ensuring rapid referral for patients with positive findings, through the introduction of a Chest Pain Assessment Unit (CPAU). This unit provides patient care and rapid access to diagnostic testing, including Troponin T testing, using the Roche point of care (POC) cardiac marker system, cobas h 232.
“Prior to opening the CPAU, patients at low risk of Acute Coronary Syndrome (ACS) were spending a long time in hospital unnecessarily, often overnight, while ACS was ruled out,” explained nurse consultant-acute medicine, Sharon Oswald. “To obtain real-time results that enable rapid decisions to be made, we introduced the Roche cobas h 232 system for point-of-care Troponin T testing. The cobas h 232 has had a huge impact on the service. Before we introduced it, Troponin T tests were batched and performed four times per day in the laboratory. There were sometimes delays in getting the bloods to the laboratory and then in getting results back. Now, with the cobas h 232 systems, we are able to obtain results in real time, which allows faster decision making.”
“The cobas h 232 system is very sensitive,” Sharon added. “A six month comparative evaluation demonstrated that we were getting comparable results to the laboratory method. We still send positives to the laboratory for confirmation but negative results do not require further confirmation. This means [we can exclude] ACS more quickly, allowing earlier discharge. Patients that require further investigation or care can be referred immediately or given a planned return appointment.”
Related Links:
Roche
Forth Valley Royal Hospital
Latest Clinical Chem. News
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Channels
Molecular Diagnostics
view channel
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read more
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more




.jpg)



